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ABSTRACT 
Objective: To determine the impact of idiopathic overactive bladder wet (OAB 
wet) severity, age and gender on health-related quality of life (HRQoL), 
productivity, treatment patterns and treatment satisfaction.  
Materials and methods: A prospective, cross-sectional online survey of adults 
in the United Kingdom was performed to screen for self-reported symptoms of 
OAB wet. Respondents completed the Kings Health Questionnaire or the 
Incontinence Quality of Life, as well as the Euroqol 5D, and the Work 
Productivity and Activity Impairment Specific Health Problem questionnaire, 
which contain questions pertaining to distress, treatment and treatment 
satisfaction.  
Results: 249 of 1126 respondents (22.1%) met the criteria for OAB wet. 
Respondents with moderate/severe OAB wet and all women experienced 
significantly worse HRQoL and work productivity than those with mild symptoms 
and all men, respectively. Among all OAB wet responders, 62.7% were 
receiving treatment for their condition, predominantly pads (40.2%); only 1.6% 
were receiving specialised treatment. Nearly one-half (44.6%) were somewhat 
or completely dissatisfied with their current treatment.   
Conclusion: In individuals with OAB wet, severity and gender negatively impact 
HRQoL and work productivity. A substantial proportion of OAB wet individuals 
were untreated, and low treatment satisfaction was reported in those receiving 
treatment. Treatment was generally conservative. 
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INTRODUCTION 
Idiopathic overactive bladder (OAB) is defined as urinary urgency, usually with 
urinary frequency and nocturia without any obvious pathology.1 In some 
patients, urgency, a sudden and strong desire to void that cannot be postponed, 
results in urge urinary incontinence (UUI). OAB wet is the accepted term for 
OAB with UUI.  
The prevalence of idiopathic OAB wet increases with age from 2% to 19% in 
women and from 0.3% to 8.9% in men within age groups 18 to 24 years and 65 
to 74 years, respectively.2 Patients with OAB wet rank UUI as one of the most 
bothersome symptoms,3 and the degree of bother increases significantly with 
UUI frequency.4 OAB wet results in significantly worse health-related quality of 
life (HRQoL), bother and sleep compared to stress urinary incontinence5,6 
impacts HRQoL, and causes distress and depression significantly more often 
than OAB dry.4,7-10 However, there is limited information on how HRQoL varies 
with UUI severity, gender or age among those with OAB wet. OAB in general 
and OAB wet also impose a burden on patient productivity, and employment 
and medical resource use,7-9,11-15 and UUI severity is significantly associated 
with productivity loss.7  
The objectives of this study were to determine the impact of idiopathic OAB 
wet severity, age and gender on HRQoL, productivity, treatment patterns and 
treatment satisfaction.  
 
MATERIALS AND METHODS 
Study design and respondents 
Primary data were collected in a prospective cross-sectional online survey of 
adults in the UK in 2014 performed by Patients Direct Limited, Scotland.  
Participants were recruited through social media, hard copy invitations 
distributed in clinics and pharmacies, and incontinence product catalogues. 
Respondents were not compensated for their participation. 
Selection began with screening for adults (aged at least 18 years) with urinary 
incontinence not associated with a neurological disease or urinary tract 
infection. To determine incontinence status, respondents were asked, “How 
often do you leak urine?”. The analysis restricted respondents further by 
excluding those with stress urinary or mixed urinary incontinence, thereby 
including only persons with urgency, the hallmark of OAB. Double incontinence 
patients were also excluded. 
 
Questionnaires  
Respondents were asked about bladder symptoms, symptom distress, HRQoL, 
work productivity, and treatment. Disease-specific HRQoL was assessed using 
the King’s Health Questionnaire (KHQ) or the Incontinence Quality of Life (I-
QoL) questionnaire, as recommended by the International Consultation on 
Incontinence.16 The administration of the KHQ and the I-QOL was alternated to 
reduce response burden. Generic health status was measured using the five 
level Euroqol 5D (EQ-5D-5L). Work productivity was assessed with the Work 
Productivity and Activity Impairment Specific Health Problem questionnaire, 
version 2.0 (WPAI-SHP). The EQ-5D-5L and the WPAI-SHP were administered 
to all respondents. 
The KHQ17,18 comprises 21 items across eight domains divided in two parts 
(Part 1: General Health perception, Incontinence Impact; Part 2: Role 
Limitations, Social Limitations, Physical Limitations, Personal Relationships, 
Emotions, Sleep/Energy, Severity/Coping Measures) and a symptoms severity 
scale (Part 3). The scores for domains in Parts 1 and 2 are transformed to a 
scale of 0-100 such that a higher score denotes a worse HRQoL in each part. 
Part 3 is scored by calculating the percentage of respondents selecting one of 
three response items asking how much they are affected (a little, moderately, a 
lot). The minimal clinically important difference (MCID) specific to OAB is at 
least five points for the domains in Parts 1 and 2.19  
The I-QOL consists of 22 items across three domains (Avoidance & Limiting 
behaviour, Psychosocial Impact, Social embarrassment). Items’ scores are 
transformed to a scale of 0-100 for all three domains and for the total score. A 
higher score indicates a better HRQoL. The MCID for the I-QOL total score and 
each domain is four points.20  
The EQ-5D-5L comprises five single item dimensions (Mobility, Self-care, Usual 
activities, Pain/discomfort, and Anxiety/depression) and a general health status 
score elicited using a visual analogue scale (EQ-5D VAS score; range: zero, 
worst health imaginable to 100, best health imaginable).21 The scores elicited 
from the five dimensions are transformed into a weighted utility index that 
ranges from zero (death) to one (full health).  
The WPAI-SHP questionnaire22 has nine items to assess the impact of a 
person’s health problem on four domains: Absenteeism, Presenteeism, Work 
productivity loss (overall work impairment/absenteeism plus presenteeism) and 
Activity impairment. For this survey, the health problem was referenced as 
“urinary incontinence”. Scores are transformed and expressed as impairment 
percentages; higher values indicate greater productivity loss and impairment. 
To our knowledge, a MCID has not been developed for either the WPAI-SHP 
specific to OAB, or for the EQ-5D-5L. 
Respondents were also asked which bladder problem caused them the most 
distress, and about treatment they had used or were currently using, treatment 
satisfaction, and alternative treatments they had considered.  
 
Statistical Analysis 
All respondents who completed the survey and met the eligibility criteria for the 
current analysis were included in the analyses.  
The number of participants responding to the survey was reported. Data were 
analyzed descriptively reporting the number and percentage for categorical 
variables and the mean and standard deviation for continuous variables. All 
variables were reported for OAB wet respondents overall, urinary incontinence 
severity, age and gender groups. In the absence of a universal definition of 
OAB wet severity, mild urinary incontinence was defined as up to three 
incontinence episodes a week (OAB wet mild), and moderate/severe urinary 
incontinence was defined as greater than this.  
Estimates for the differences between OAB wet mild and moderate/severe 
groups were obtained for continuous and categorical outcomes using linear and 
ordinal logistic regression models respectively, adjusting for gender and age. 
Models used to compare age groups were adjusted for gender and vice versa. 
P - values were reported for between-group differences. The difference across 
all age groups was tested and p - value reported (pairwise age group 
differences were not investigated). 
For all analyses, a p - value <0.05 was considered to indicate a statistically 
significant difference. Statistical analyses were performed using SAS software, 
Version 9.2© (Cary, NC, USA). 
MCIDs for the KHQ and the I-QOL were applied to the domains with a between-
group adjusted difference with a p-value < 0.05. 
   
RESULTS  
Respondent characteristics and symptoms 
From a total of 1126 respondents, 249 (22.1%) met the selection criteria for 
OAB wet comprising 122 (49.0%) with mild and 127 (51.0%) with 
moderate/severe urinary incontinence. The mean age of respondents with mild 
or moderate/severe OAB wet was 57.3 and 58.1 years, respectively; the mean 
age of the overall sample was 57.7 years.  Overall, the most populated age 
group was 60-69 years (30.1%), and the least populated was under 40 years 
(10.4%). Similarly, in the mild and moderate/severe OAB wet groups, the most 
populated was 60-69 years (30.3% and 29.9%, respectively), and the least 
populated was under 40 years (11.5% and 9.4%, respectively). Just over one-
half of all respondents with OAB wet were male (54.6%). Over half of those with 
moderate/severe (55.1%) OAB wet were male. 
 
HRQoL 
Compared with respondents with mild OAB wet, those with moderate/severe 
OAB wet reported significantly worse HRQoL, as measured using the KHQ 
(Part 1, p < 0.001; and Part 2, p < 0.001), the I-QOL (total score, p = 0.016; 
Avoidance and limiting behaviour, p = 0.049; Psychosocial impact, p = 0.048; 
Social embarrassment, p = 0.002), and the EQ-5D-5L (utility score, p = 0.014), 
adjusted for sex and age (Table 1, Figure 1). Regardless of severity of urinary 
incontinence, age or gender, respondents reported the greatest impact of 
symptoms on the domains Incontinence impact (KHQ Part 1) (Figure 2) and 
Social embarrassment (I-QOL) (Figure 1).  
The difference between respondents with mild and moderate/severe urinary 
incontinence was statistically significant for all KHQ domains (p ≤ 0.019) with 
the exception of General health perception (p = 0.072), indicating a worse 
HRQoL in physical, emotional, and social aspects of life for those with more 
severe OAB wet (Figure 2).  
Considering the differences between respondents with mild and those with 
moderate/severe urinary incontinence, the a priori determined MCIDs of at least 
five points for all KHQ domains (Parts 1 and 2) were exceeded. The MCID of at 
least four points for the total and domain scores of the I-QOL was also 
exceeded. 
Females with OAB wet reported significantly worse HRQoL compared to males 
in five out of eight KHQ domains (Incontinence impact, p = 0.005; Role 
limitations, p < 0.001; Physical limitations, p = 0.002; Sleep/energy, p = 0.001; 
Severity measures, p < 0.001), in KHQ Part 1 (p = 0.005), KHQ Part 2 (p = 
0.010), the overall and all domain scores of the I-QOL (p ≤ 0.005), and the EQ-
5D-5L utility score (p = 0.002) (Table 1).  
The total score (p = 0.003) and all three domains of the I-QOL (Avoidance and 
limiting behaviour, p = 0.032; Psychosocial impact, p < 0.001; Social 
embarrassment, p = 0.023) showed a significantly worse HRQoL across age 
groups; those aged at least 70 years reported the best, and those aged 40-49 
years the worst HRQoL (Table 1). Neither the EQ-5D-5L utility score (p = 
0.806), nor any KHQ scores (p ≥ 0.094) showed a significant difference by age 
group.  
The most distressing bladder problems (“a lot” in Part 3 KHQ) were urgency 
(59.3%), frequency (54.2%) and urge incontinence (51.7%) in the 
moderate/severe group, and frequency (45.0%), urgency (37.7%) and nocturia 
(32.3%) in the mild group.  
 
Employment and Productivity 
According to responses to the WPAI-SHP, 46.2% of OAB wet responders 
(43.3% of those with moderate/severe OAB wet, 49.2% of those with mild OAB 
wet) were employed (Table 2). Employment rates were similar between genders 
(males 47.8%; females 44.2%) and decreased with age. Significantly more 
respondents with moderate/severe OAB wet reported worse overall Work (p = 
0.003) and Activity impairment (p < 0.001) and significantly more Impairment 
while working due to incontinence (presenteeism) (p = 0.001) compared to the 
mild group (Table 2). The difference between groups in Work time missed due 
to incontinence (absenteeism) was not statistically significant (p = 0.677). 
 
Treatment 
Among respondents with mild or moderate/severe OAB wet, 42.6% and 32.3%, 
respectively, were not receiving any treatment for their condition at the time of 
the survey (Figure 3). Use of specialised treatments (referred to as: ‘drug 
injections into the bladder (e.g. onabotulinumtoxinA)’, ‘temporary electrical 
stimulation’, ‘permanent implantable device for electrical stimulation’ and 
‘surgery’) was reported only by 1.6% of respondents in both severity groups 
(Figure 3). The most reported treatment combination in both severity groups 
was pads plus oral medication (23.8% in both groups).  
When asked about treatments they had ever used, 29.3% of respondents with 
OAB wet reported never having received treatment. Specialised treatments had 
only ever been used by 10.0% of all OAB wet respondents, and 9.0% and 
11.1% of those with mild or moderate/severe OAB wet, respectively (Figure 4a). 
None of the respondents had ever received an implantable device for electrical 
stimulation (Figure 4). 
Overall, 44.6% of respondents were dissatisfied with their current treatment, 
18.5% reported satisfaction, and 36.9% were ‘neither satisfied nor dissatisfied’. 
Satisfaction with current treatment did not vary by severity (p = 0.055) or age (p 
= 0.178), but did with gender, with more females reporting dissatisfaction (p = 
0.037) (Figure 5).  
When asked if they would consider seeking alternative treatments to those they 
already tried, 84.7% (n=211) OAB wet respondents answered positively. Of 
these, one-third would try specialised treatments: 33.2 % surgery, 28.9% drug 
injections into the bladder, 19.4% temporary electrical stimulation, and 17.1% 
permanent implantable device for electrical stimulation.  
DISCUSSION 
The results demonstrate that those with moderate/severe urinary incontinence 
and women experienced statistically and clinically significantly worse disease-
specific and generic HRQoL than those with mild urinary incontinence and men, 
respectively. In addition, impairment while working, overall work impairment and 
activity impairment, all due to incontinence, were significantly worse for the 
moderate/severe group.  
Treatment was not ongoing for 37% of all OAB wet respondents, and when 
treated, pads were most frequently used. Specialised treatment options were 
rarely prescribed in spite of up to 33% of respondents having considered them. 
Low levels of satisfaction with treatment were prevalent. These findings may be 
indicative of limited access to specialised treatments in this patient population.  
A strength of the current study is that the population was carefully selected to 
preserve as much as possible a sample with idiopathic OAB wet, thereby 
excluding those with a neurogenic etiology, OAB dry, double and stress 
incontinence. Also, the EQ-5D-5L was selected rather than the 3L version 
because of its improved convergent validity and discriminatory power.23 All 
three questionnaires ask respondents about the present thereby reducing the 
risk of recall bias. Moreover, the statistical analyses ruled out confounding 
variables such as age and gender, when appropriate.  
A limitation is that the respondents described their own bladder problems from 
which symptoms of OAB wet were assumed. However, the a priori selection 
criteria, the opportunity to reduce the embarrassment that results when 
sufferers consult their healthcare provider and potentially inhibits truthful 
responses, and the lack of filtering respondents by a healthcare provider may, 
in part, counteract this. It was not possible to exclude people with concomitant 
urological conditions (e.g. benign prostatic hyperplasia, cystocoele) that may 
result in similar bladder symptoms to those associated with OAB. However, 
while our sample may not be representative of the overall OAB wet population, 
the majority (54.6%) are men similar to data reported by Stewart et al.2  
Without published MCID estimates for the EQ-5D-5L or the WPAI-SHP specific 
to OAB wet, the clinical relevance of the differences between groups for these 
could not be determined. Reference by previous authors to a seven point WPAI-
SHP MCID9 is based on data elicited from persons with insomnia or Crohn’s 
disease who may have perceived changes in their health status differently to 
persons with OAB. Furthermore, we did not collect data on primary care or 
specialist visits, or hospitalizations based on the concern that patient recall for 
these parameters bares little correlation to actual events.24,25  
CONCLUSIONS 
Adults with moderate/severe OAB wet, and women with any severity of OAB 
wet experienced statistically and clinically significantly worse HRQoL and higher 
rates of work impairment than those with mild OAB wet and men, respectively. 
Many with moderate/severe symptoms had never received, and at the time of 
the survey were not receiving, any treatment. When prescribed, treatment was 
mainly in the form of pads or other conservative options with limited access to 
specialised treatments. Treatment satisfaction was generally low.        
While significant associations between HRQoL and increasing bother and 
severity of bladder symptoms among OAB patients has been reported 
previously,7,9,26-28 differences in HRQoL, productivity and treatment between 
groups categorised by severity, age and gender have not been documented. 
Therefore, the present study contributes new information to the repository of 
knowledge about OAB wet severity. Future research should investigate access 
to both conservative and specialised treatment and its impact on patients’ 
satisfaction. 
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TABLES AND LEGENDS 
Table 1 Mean health-related quality of life scores (standard deviation (SD)) by urinary incontinence severity, gender and age 
and comparisons (adjusted analyses) between groups  
Questionnaire Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB 
wet 
respondent
s (n=249) 
<40 
years 
(n=26) 
40-49 
years 
(n=33) 
50-59 
years 
(n=70) 
60-69 
years 
(n=75) 
≥70 
years 
(n=45) 
Males 
(n=136
) 
Female
s 
(n=113) 
King’s Health Questionnaire * (n=123) 
Part 1 86.4 (35.7) 114.2 (30.3) ɸ 100.2 100.0 84.6 100.7 110.7 91.0 91 109 
Questionnaire Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB 
wet 
respondent
s (n=249) 
<40 
years 
(n=26) 
40-49 
years 
(n=33) 
50-59 
years 
(n=70) 
60-69 
years 
(n=75) 
≥70 
years 
(n=45) 
Males 
(n=136
) 
Female
s 
(n=113) 
(35.8) (34.1) (27.2) (36.0) (36.0) (37.3) (33.3) (36.1) § 
Part 2 
217.4 
(114.8) 
340.4 (161.2) ɸ 278.9 
(152.3) 
285 
(123.4
) 
237 
(132.7
) 
302 
(175.8
) 
292 
(148.2
) 
224 
(131.4
) 
237 
(134.5) 
321 
(158.9) 
∞ 
Incontinence Quality of life questionnaire ** (n=126) 
Questionnaire Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB 
wet 
respondent
s (n=249) 
<40 
years 
(n=26) 
40-49 
years 
(n=33) 
50-59 
years 
(n=70) 
60-69 
years 
(n=75) 
≥70 
years 
(n=45) 
Males 
(n=136
) 
Female
s 
(n=113) 
Total score 
56.7 (21.9) 47.1 (22.4) ƺ 51.7 (22.6) 52.9 
(22.9) 
38.4 
(25.1) 
46.0 
(21.2) 
54.9 
(20.4) 
66.5  
(16.1) 
ɸ 
58.0 
(19.6)  
41.5 
(23.9) ɸ 
Avoidance & 
limiting 
52.9 (19.3) 45.7 (20.7) ∩ 49.1 (20.3) 51.7 
(21.1) 
38.1 
(20.7) 
48.0 
(19.1) 
47.7 
(19.3) 
61.8  
(17.1) 
55.6 
(17.8)  
38.2 
(19.7) ɸ 
Questionnaire Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB 
wet 
respondent
s (n=249) 
<40 
years 
(n=26) 
40-49 
years 
(n=33) 
50-59 
years 
(n=70) 
60-69 
years 
(n=75) 
≥70 
years 
(n=45) 
Males 
(n=136
) 
Female
s 
(n=113) 
behaviour ɸ 
Psychosocial 
impact 
63.7 (26.4) 54.3 (25.8) ∩ 58.8 (26.4) 60.0 
(26.8) 
42.2 
(29.9) 
49.7 
(23.9) 
65.7 
(23.6) 
75.7  
(16.5) 
ɸ 
64.5 
(22.5)  
49.2 
(29.6) § 
Social 50.1 (23.5) 36.2 (25.6) ≈ 42.8 (25.5) 42.1 31.8 36.0 46.8 57.6 48.7 33.0 
Questionnaire Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB 
wet 
respondent
s (n=249) 
<40 
years 
(n=26) 
40-49 
years 
(n=33) 
50-59 
years 
(n=70) 
60-69 
years 
(n=75) 
≥70 
years 
(n=45) 
Males 
(n=136
) 
Female
s 
(n=113) 
embarrassmen
t 
(23.8) (27.0) (25.9) (22.6) (22.9) 
ɸ 
(23.3)  (26.1) ≈ 
EQ-5D-5L ** 
Utility score 
0.769 
(0.244) 
0.692 (0.263)∞ 0.730 
(0.256) 
0.692 
(0.290
0.720 
(0.280
0.714 
(0.234
0.734 
(0.277
0.775 
(0.217
0.777 
(0.204) 
0.674 
(0.298)
Questionnaire Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB 
wet 
respondent
s (n=249) 
<40 
years 
(n=26) 
40-49 
years 
(n=33) 
50-59 
years 
(n=70) 
60-69 
years 
(n=75) 
≥70 
years 
(n=45) 
Males 
(n=136
) 
Female
s 
(n=113) 
) ) ) ) ) ≈ 
Visual 
analogue 
scale score 
69.2 (22.2) 67.3 (21.1) 68.2 (21.6) 68.1 
(21.9) 
63.9 
(23.6) 
65.1 
(20.2) 
69.4 
(22.0) 
74.5 
(20.8) 
71.0 
(20.3) 
65.0 
(22.8) ƺ 
Key: *, a higher score indicates a worse HRQoL; **, a higher score indicates a better HRQoL; ɸ, P < 0.001; §, P = 0.005; ≈, P 
= 0.002; ∞, P = 0.01; #, P = 0.03; ƺ, P = 0.04; ∩, P = 0.05 
TABLES AND LEGENDS 
Table 2 Work Productivity and Impairment Questionnaire scores (means and standard deviations (SDs)) by urinary 
incontinence severity, gender and age and comparisons (adjusted analyses) between groups  
 Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB wet 
respondent
s (n=249) 
<40 
years 
(n=26
) 
40-49 
years 
(n=33
) 
50-59 
years 
(n=70
) 
60-69 
years 
(n=75
) 
≥70 
years 
(n=45
) 
Males 
(n=136
) 
Female
s 
(n=113) 
Currently 
employed, n 
60 (49.2) 55 (43.3) 115 (46.2) 18 
(69.2) 
26 
(78.8) 
47 
(67.1) 
21 
(28.0) 
3 
(6.7) 
65 
(47.8) 
50 
(44.2) 
 Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB wet 
respondent
s (n=249) 
<40 
years 
(n=26
) 
40-49 
years 
(n=33
) 
50-59 
years 
(n=70
) 
60-69 
years 
(n=75
) 
≥70 
years 
(n=45
) 
Males 
(n=136
) 
Female
s 
(n=113) 
(%) 
Mean (SD) % 
of work time 
missed due to 
incontinence 
(absenteeism)  
1.7 (7.6) 1.1 (4.3) 1.4 (6.2) 3.9 
(12.4) 
1.6 
(6.4) 
0.8 
(3.0) 
0.0 
(0.0) 
0.5 
(1.5) 
1.2 
(4.7)  
1.3 (6.5)  
 Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB wet 
respondent
s (n=249) 
<40 
years 
(n=26
) 
40-49 
years 
(n=33
) 
50-59 
years 
(n=70
) 
60-69 
years 
(n=75
) 
≥70 
years 
(n=45
) 
Males 
(n=136
) 
Female
s 
(n=113) 
Mean (SD) % 
of impairment 
while working 
due to 
incontinence 
(presenteeism
20 (20) 33 (24) ∞ 26 (23) 41 
(22) 
31(26
) 
25 
(24) 
16 
(17) 
20 
(23)  
23 (22)  29 (25)  
 Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB wet 
respondent
s (n=249) 
<40 
years 
(n=26
) 
40-49 
years 
(n=33
) 
50-59 
years 
(n=70
) 
60-69 
years 
(n=75
) 
≥70 
years 
(n=45
) 
Males 
(n=136
) 
Female
s 
(n=113) 
) 
Mean (SD) % 
Overall work 
impairment 
due to 
incontinence 
21.2 (22) 33.5 (24.4) # 27.1 (23.9)  42.4 
(24.2) 
32.1 
(27.0) 
25.7 
(24.5) 
15.9 
(17.3) 
20.3 
(23.1) 
Ø 
23.9 
(23.3) 
30.0 
(25.9) 
 Mild urinary 
incontinenc
e (n=122) 
Moderate/sever
e urinary 
incontinence 
(n=127) 
All OAB wet 
respondent
s (n=249) 
<40 
years 
(n=26
) 
40-49 
years 
(n=33
) 
50-59 
years 
(n=70
) 
60-69 
years 
(n=75
) 
≥70 
years 
(n=45
) 
Males 
(n=136
) 
Female
s 
(n=113) 
Mean (SD)  % 
Activity 
impairment 
due to 
incontinence 
28 (25) 42 (27) ɸ 35 (27) 46 
(27) 
43 
(29) 
37 
(25) 
36 
(27) 
34 
(27) 
30 (24) 42 (27) 
ɸ 
Key: *, a higher score indicates decreased productivity; ɸ, P < 0.001; ∞, P = 0.01 
 
